Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company whose news flow centers on rare neuroendocrine diseases and MC4R pathway–targeted therapies. The company’s updates frequently highlight global commercial performance of its lead product IMCIVREE (setmelanotide), regulatory milestones, and clinical data across multiple rare obesity indications.
Investors following RYTM news can expect regular announcements on net product revenues from global sales of IMCIVREE, including the relative contributions from the United States and international markets. Rhythm also issues press releases on reimbursement developments, such as public reimbursement agreements for IMCIVREE in Canadian provinces and under federal programs for patients with Bardet-Biedl syndrome–related obesity.
Clinical and regulatory news is a major focus. Rhythm reports on Phase 3 trials like TRANSCEND in acquired hypothalamic obesity and EMANATE in genetically caused MC4R pathway diseases, as well as exploratory and Phase 2 studies in Prader-Willi syndrome and other rare conditions. Updates often include topline efficacy and safety data, cardiometabolic outcomes, and patient- and caregiver‑reported measures presented at scientific meetings.
Regulatory communications include FDA actions on supplemental New Drug Applications, PDUFA goal dates and extensions, and EMA validation of Type II variations to existing marketing authorizations. Rhythm also provides information on development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism.
For users tracking RYTM, this news feed offers a centralized view of earnings releases, clinical trial readouts, regulatory decisions and access milestones related to IMCIVREE and Rhythm’s broader rare disease pipeline.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will report first quarter 2026 financial results on Tuesday, May 5, 2026 with a live conference call and webcast at 8:00 a.m. ET. The company also announced a fireside chat by CFO Hunter Smith at the Needham Virtual Healthcare Conference on April 16, 2026 at 11:00 a.m. ET.
Live webcasts for both events will be available in the Investor Relations "Events and Presentations" section at the company's investor website, with archived replays available approximately two hours after the earnings call and for 30 days after each event.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced Board changes on April 3, 2026: Kim Popovits was appointed director and Ed Mathers will depart.
Kim brings more than 40 years of life‑sciences leadership, including CEO and chairman roles at Genomic Health and senior commercialization roles at Genentech. Ed served on the Board since 2013.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a positive CHMP opinion recommending expansion of IMCIVREE® (setmelanotide) to treat obesity and control hunger in adults and children aged 4+ with acquired hypothalamic obesity due to hypothalamic injury or impairment.
A final European Commission decision is anticipated in the second quarter of 2026; the CHMP opinion follows an FDA approval announced last week.
PANTHERx Rare was chosen by Rhythm Pharmaceuticals (Nasdaq: RYTM) as the exclusive U.S. specialty pharmacy for the expanded indication of IMCIVREE (setmelanotide) for adults and children aged 4 and older with acquired hypothalamic obesity, announced March 20, 2026.
PANTHERx will deploy its RxARECARE model for individualized case management, education, and financial and insurance navigation. PANTHERx has served as IMCIVREE's exclusive pharmacy for certain genetic obesity indications since 2020.
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced FDA approval of IMCIVREE (setmelanotide) for acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older. Approval was based on the Phase 3 TRANSCEND trial showing a -18.4% placebo-adjusted BMI reduction.
IMCIVREE is available immediately in the U.S.; Rhythm estimates ~10,000 people in the U.S. live with acquired HO. The company will host a conference call today at 7:00 p.m. ET.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported topline Phase 3 EMANATE results: the four genetic substudies did not meet prespecified primary endpoints for placebo-adjusted BMI change at Week 52.
Post hoc LOCF analyses showed statistically significant BMI reductions in POMC/PCSK1 Hets (−5.5%, p=0.0010) and SRC1 (NCOA1) (−6.2%, p<0.0001). No new safety signals were observed. A conference call was scheduled for 4:30 p.m. ET on March 16, 2026.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported additional positive 52-week data from its global Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obesity. Results showed a -18.8% placebo-adjusted BMI reduction (N=142) and mean BMI change of -16.4% on drug versus +2.4% on placebo (p<0.0001).
The dataset adds 12 Japanese patients and 10 supplemental patients. The company set a PDUFA goal date of March 20, 2026 for its supplemental NDA and will submit the final data package to the FDA on March 2, 2026. EMA CHMP opinion is anticipated in Q2 2026.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported Q4 2025 IMCIVREE net product revenue of $57.3 million and full-year 2025 product revenue of $194.8 million. Cash, cash equivalents and short-term investments were $388.9 million as of Dec 31, 2025.
The company disclosed a PDUFA goal date of March 20, 2026 for a sNDA seeking approval of setmelanotide in acquired hypothalamic obesity (HO), reported positive Phase 2 open-label extension data for bivamelagon, and plans multiple March 2026 topline readouts.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 with a live conference call and webcast at 8:00 a.m. ET. Participants may register to join; joining 10 minutes early is recommended.
CEO David Meeker will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 at 11:10 a.m. ET. Both webcasts will be archived on Rhythm’s Investor Relations website; the earnings call archive will be available about two hours after the call and both recordings will remain for 30 days.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that CFO Hunter C. Smith will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 11:00 a.m. ET in New York. The session will be webcast and replayed for 30 days on the company website.